Citius Oncology, Inc. (CTOR) - Total Assets
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) holds total assets worth $100.70 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Citius Oncology, Inc. - Total Assets Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see CTOR stock market capitalisation for the company's overall valuation and market capitalisation.
Citius Oncology, Inc. - Asset Composition Analysis
Current Asset Composition (September 2025)
Citius Oncology, Inc.'s total assets of $100.70 Million consist of 27.3% current assets and 72.7% non-current assets. Review Citius Oncology, Inc. balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $22.29 Million | 22.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $73.40 Million | 72.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Citius Oncology, Inc. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Citius Oncology, Inc.'s current assets represent 27.3% of total assets in 2025, an increase from 6.3% in 2022.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2025, up from 0.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, a decrease from 93.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 72.7% of total assets.
Citius Oncology, Inc. Competitors by Total Assets
Key competitors of Citius Oncology, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Citius Oncology, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.50 | 0.36 | 11.85 |
| Quick Ratio | 0.12 | 0.05 | 11.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-29.39 Million | $-31.70 Million | $345.51K |
Citius Oncology, Inc. - Advanced Valuation Insights
This section examines the relationship between Citius Oncology, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | 19.6% |
| Total Assets | $100.94 Million |
| Market Capitalization | $75.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Citius Oncology, Inc.'s assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Citius Oncology, Inc.'s assets grew by 19.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Citius Oncology, Inc. (2022–2025)
The table below shows the annual total assets of Citius Oncology, Inc. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $100.94 Million | +19.64% |
| 2024-09-30 | $84.37 Million | +76.74% |
| 2023-09-30 | $47.73 Million | +11.82% |
| 2022-09-30 | $42.69 Million | -- |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary… Read more